The physiological effects of ethanol are dependent upon the amount and duration of consumption. Chronic excessive consumption can lead to diseases such as liver cirrhosis, and cardiac arrhythmias, while chronic moderate consumption can have therapeutic effects on the cardiovascular system. Recently, it has also been observed that acute administration of ethanol to animals prior to an ischemic event provides significant protection to the heart. This review focuses on the different modalities of chronic vs. acute ethanol consumption and discusses recent evidence for a protective effect of acute ethanol exposure and the possible use of ethanol as a therapeutic agent.
Introduction
The World Health Organization estimates that Americans over the age of 15 years drink on average more than 8.6 liters of ethanol per year [World Health Organization, 2007] and the Centers for Disease Control estimates that in 2001, there were 75,766 deaths attributed to the harmful effects of ethanol consumption [CDC, 2004] . While excessive ethanol consumption can have negative effects, acute and chronic moderate ethanol consumption has been shown to have beneficial therapeutic effects. These effects have been well documented for the cardiovascular system in many epidemiological and laboratory studies. However, many factors such as the amount and type of ethanol consumed, and the duration of consumption determine the degree of protection afforded by ethanol. Excessive and sustained ethanol consumption can result in cancer, liver disease and cardiac arrhythmias, all of which can negate the beneficial effects of ethanol on the cardiovascular system. Therefore, any discussion of ethanol as a potential therapeutic agent must be closely compared with the negative effects of excessive consumption.
This review will focus on the current state of research into the protective effects of excessive vs moderate ethanol consumption on the heart. We will briefly discuss proposed mechanisms of chronic moderate ethanol-mediated protection and then will focus on the cellular-mediated events associated with acute ethanol consumption and cardiac protection. We will contrast the preconditioning-like effect of ethanol with ischemic preconditioning and compare protein kinase C (PKC) signaling mechanisms between the two pathways. The current discrepancies in ethanol-mediated protection and implications of ethanol use as a therapeutic agent for treatment of ischemic conditions will also be discussed.
The cardiovascular epidemiology of ethanol consumption and the French paradox Historians have suggested that beer may have preceded bread as a dietary staple and fermented beverages may have existed as early as 10,000BC [Patrick, 1952 , Braidwood Rj, 1953 , Hanson, 1995 . Historically, in spite of the damaging effects of ethanol on human physiology, ethanol has been consumed for its intoxicating effects. However, in the last two decades it has become evident that drinking ethanol may also have beneficial therapeutic effects on the human cardiovascular system. This observation was first made by Samuel Black in 1819, who attributed the lower rates of angina found in French vs Irish populations to ''French habits and modes of living'' [Black 1819] . While many studies since then have focused on the protective effects of ethanol on the heart, the MONICA project, a worldwide monitoring system for cardiovascular diseases, led to Renaud and De Lorgeril's [1992] proposal of the French paradox. The MONICA project revealed that in spite of a diet high in saturated fats and high total serum cholesterol levels, the inhabitants of the French towns of Toulouse and Lille had significantly lower levels of mortality associated with coronary heart disease [Tuomilehto et al., 1989 , Who, 1989 ]. Renaud associated this with the moderate consumption of wine. Since then, many epidemiological studies have looked at the relationship between moderate ethanol consumption and coronary heart disease and found that there is a significant correlation between the amount and type of ethanol consumed and total mortality [Gronbaek et al. 2004 [Gronbaek et al. , 2000 Mukamal et al. 2001; Gaziano et al. 2000; Thun et al. 1997; Goldberg et al. 1994; Maclure 1993; Klatsky et al. 1992] . For an excellent discussion of these studies, see the recent review by Kloner and Rezkalla [2007] .
Whereas moderate ethanol consumption can prevent or even reduce the risk of coronary artery disease and cardiac ischemia, consumption of large amounts over a lifetime can actually increase mortality. The paradoxical effect of different amounts of consumed ethanol is often expressed as J-shaped or U-shaped correlations. Recently, Di Castelnuovo and colleagues published a thorough meta-analysis study in which they looked at the link between ethanol and mortality [Di Castelnuovo et al., 2006] . Their analysis showed that maximum decreases in the relative risk of total mortality occur with 6-10 g (12-14g ¼ one drink) of ethanol being consumed per day (Table 1) [Dufour, 1999 , Brick, 2006 . There is an inverse correlation between ethanol consumption and total mortality up to 40 g/day after which the relative risk of total mortality increases almost linearly. In addition to this, Corrao et al. [2004] conducted a meta-analysis on 156 published articles from 1966 to 1998 and found strong trends for increased risks associated with as little as 25 g/day of ethanol for head and neck cancers, hypertension, liver cirrhosis, chronic pancreatitis, injuries and violence. Additionally, rates above 100 g/day were associated with increased risk for coronary artery disease and ischemic stroke. In addition to these effects, ethanol at these concentrations can have other negative cardiovascular effects including cardiomyopathies [Piano, 2002] , and cardiac arrhythmias [Mukumal, 2007] . This was evidenced in a study by Rossinen et al. [1999] who showed that intravenous infusion of ethanol (0.72 g/kg/h) into 22 men with stable coronary artery disease (CAD) and 10 control patients, caused prolonged elongation of ventricular repolarization regardless of CAD suggesting that ethanol can disrupt the electrical signaling pathways in the heart [Rossinen et al. 1999 ]. While they did not attribute this to changes in autonomic regulation, it has been suggested that moderate ethanol consumption can expose patients with stable CAD to autonomic dysregulation of heart rate [Rossinen et al. 1997 ] increasing the risk of a silent ischemic event [Rossinen et al. 1996] . Furthermore, in patients with ethanol-induced atrial fibrillation, ethanol intoxication increased beta adrenoceptor density suggesting increased sympathetic stimulation [Maki et al. 1998 ]. A possible role of PKC in this effect is discussed below. Therefore, although moderate consumption of ethanol may have beneficial effects on the heart, the same or greater levels are associated with increased risk for other life-threatening conditions, and when used in excess negates the protective cardiovascular effects. The use of ethanol as a cardioprotectant must therefore be done with caution and the amount and type of ethanol consumed must be taken into account.
Mechanisms of ethanol-mediated protection
The protective effects of chronic moderate ethanol consumption on the cardiovascular system have been attributed to improved blood lipid profiles, reduced blood pressure, increased coronary blood flow, reduced thrombosis and direct preconditioning-like effects on cardiomyocytes. Because the units of ethanol amounts in various studies vary, we provide Table 1 , which converts the dose equivalent of a single alcoholic beverage [Brick 2006; Dufour 1999]. in humans on an empty stomach. We also provide the lethal dose of ethanol in non-tolerant individuals to emphasize the danger of binge drinking.
Early studies in rats that were chronically treated with ethanol found an elevation in serum cholesterol bound to high density lipoprotein (HDL) [Hirayama et al. 1979 ]. These increases were later shown to be due to de novo synthesis of HDL [Cluette et al. 1984] and were found in humans as well [McConnell et al. 1997; Dai et al. 1985] . In addition to elevated HDL levels, chronic ethanol consumption decreased LDL levels [Langer et al. 1992; Taskinen et al. 1987] . Excessive ethanol consumption negatively correlates with hypertension. However, the relationship seems to follow a similar J-or U-shaped curve, where lower amounts of ethanol may be beneficial. In a study involving young adults (18-26 years), those who consumed one to less than two drinks per day had lower systolic blood pressures compared to those who either abstained, drank less than one drink per day or more than two drinks per day [Gillman et al. 1995] . Older populations (50 years and older) of moderate ethanol consumers exhibited similar effects [Jackson et al. 1985] . These results were recapitulated in laboratory rats and were found to be dependent upon the activation of the ANP and BNP systems as well as diminished aldehyde accumulation [Vasdev et al. 2006; Vasdev et al. 1999; Guillaume et al. 1996a Guillaume et al. , 1996b . Therefore, some of the beneficial effects of moderate ethanol consumption on the cardiovascular system may be due to improved blood lipid profiles, decreased blood pressure and other direct effects. However, these benefits may be outweighed by the adverse effects depending on the dose consumed.
Endothelial dysfunction results in diminished coronary vascular flow reviewed in [Cohen, 1995] . Several studies have suggested that administration of antioxidants such as vitamin C and glutathione can protect the endothelium and increase coronary blood flow [Kugiyama et al. 1998; Taddei et al. 1998; Solzbach et al. 1997 ]. Because of the effects of these antioxidants, protective effects of red wine have often been attributed to polyphenols, which in addition to increasing nitric oxide synthase (NOS) activity [Zenebe et al. 2003; Hattori et al. 2002] , have the ability to act as antioxidants [Ray et al. 1999; Maxwell et al. 1994; Frankel et al. 1993 ]. However, ethanol alone can also increase coronary flow without a direct antioxidant effect [Kiviniemi et al. 2007 ] by increasing NOS activity [Venkov et al. 1999 ] and NOS expression [Kleinhenz et al. 2008; Abou-Agag et al. 2005; Venkov et al. 1999] . Another mechanism by which ethanol improves coronary blood flow is through inhibition of thrombus formation. Thrombus formation requires the aggregation of platelets, which once formed, leads to downstream tissue ischemia reviewed in [Churchill et al. 2008] . Folts and collaborators found that 1.0 ml/kg of pure ethanol as well as red wine and grape juice prevents platelet activation in a model of coronary artery thrombosis [Demrow et al. 1995; Keller et al. 1988 ]. Similar to the effects on coronary blood flow, the mechanism of diminished platelet aggregation involved a polyphenoldependent increase in NO generation [Freedman et al. 2001] . Moderate ethanol consumption can also increase endothelial cell-and monocytemediated fibrinolysis, which helps prevent thrombus formation [Tabengwa et al. 2002; Aikens et al. 1998 ].
An interesting link between antioxidants and NO is noticeable through these distinct mechanisms.
The improvement in elevated blood pressure associated with moderate ethanol consumption is due, in part, to the prevention of aldehyde accumulation and protein-aldehyde adduct formation [Vasdev et al. 2006 [Vasdev et al. , 1999 . Another study demonstrated that one common toxic aldehyde, 4-hydroxynonenal (4-HNE), inhibits NOS activity in a leptin-induced model of hypertension [Beltowski et al. 2005 ]. In addition, the beneficial effects of ethanol on coronary flow and thrombus formation are dependent upon antioxidant capabilities of phenolic compounds as well as increased activity of NOS [Kleinhenz et al. 2008; Venkov et al. 1999; Abou-Agag et al. 2005] . Interestingly, 4-HNE diminishes NO generation through the NF-kB-dependent downregulation of NOS protein levels [Hattori et al. 2001 ] and indirectly, by inhibiting dimethylarginine dimethylamino-hydrolase (DDAH-1), an enzyme which regulates the activity of NOS [Forbes et al. 2008] . Therefore, it is plausible that ethanol may act as a cardioprotectant through a mechanism involving the downregulation of toxic aldehydes such as 4-HNE, thereby decreasing oxidative stress and improving coronary flow reserve, blood pressure and decreasing thrombus formation.
Ethanol can also have direct protective effects on cardiomyocytes. We have previously shown that exposure to as little as 10 mM ethanol 10-20 minutes prior to the ischemic event protects the intact adult rat heart from prolonged ischemic damage ]. This was the first observation that acute ethanol treatment could protect the heart from subsequent ischemia. The signaling pathways in ethanol-mediated preconditioning share some similarities with those of ischemic preconditioning (IPC) pathways. It has been well established that the heart is protected from ischemia/reperfusion injury (I/R) when subjected to brief periods of ischemia prior to the prolonged ischemic event [Mitchell et al. 1995; Das et al. 1993; Flack et al. 1991; Murry et al. 1986 ]. Since the initial discovery by Murry et al. much work has gone into elucidating the cellular and molecular mechanisms involved in this pathway. The signaling pathway of IPC is triggered by ischemic metabolites, such as adenosine and ROS, resulting in the activation of intermediary signaling molecules, such as PKC and other kinases such as Akt and ERK1/2 (collectively termed reperfusion injury salvage kinases, or RISKs) [Yellon et al. 2005] , that transmit the signal to downstream end-effectors [Yellon et al. 2003] . A variety of mitochondrial end-effectors of IPC have been proposed including mitochondrial-ATP-sensitive K þ channels (mitoKATP), the mitochondrial permeability transition pore (MPTP) and components of the electron transport chain (reviewed in Yellon et al. 2003 and Budas et al. 2007a ). An alternative mechanism of "PKC cardioprotection is via regulation of gap junction permeance and reduction in reperfusion arrythmias. During ischemia, the primary gap junction protein, connexin 43, (Cx43) becomes dephosphorylated, and translocates from gap junctions to intracellular structures, resulting in increased gap junction permeance and conductance [Beardslee et al. 2000 ].
Connexin 43 is a critical target for IPC as evidenced by the fact that mice deficient in this enzyme have increased arrhythmias after coronary occlusion ] and cannot be preconditioned [Schwanke et al. 2002] . A number of studies have established Cx43 as a "PKC substrate [Hund et al. 2007; Bowling et al. 2001; Doble et al. 2001 Doble et al. , 2000 and work from our lab has demonstrated that selective activation of "PKC reduces reperfusion arrythmias ]. Therefore, it is possible that by phosphorylating Cx43, "PKC prevents intracellular translocation of Cx43 and thus preserves gap junction integrity. A recent study, using a combination of "PKC-knockout mice and "PKC-selective regulators, demonstrated that "PKC activation is essential for IPC-induced preservation of Cx43 at gap junctions [Hund et al. 2007] . It is interesting to speculate whether ethanol induced activation of "PKC also results in Cx43 phosphorylation, although to our knowledge this has yet to be demonstrated.
In contrast to IPC, ethanol-mediated preconditioning may not be dependent upon adenosine receptors or reactive oxygen species and Krenz et al. [2002] suggest that ethanol probably acts somewhere downstream of membrane receptors. This is in contrast to our data, which suggests that activation of the adenosine receptor is necessary for ethanol-mediated cardiac protection ]. However, these inconsistencies can be reconciled by the duration of ethanol exposure and chronic vs acute modes of ethanol administration. As mentioned earlier, activation of mitochondrial KATP channels mediates, at least in part, the downstream protective effects of IPC signaling [Dos Santos et al. 2002; Liu et al. 1998; Garlid et al. 1997 ]. Furthermore, mitochondrial KATP channel activation can increase mitochondrial matrix volume [Kowaltowski et al. 2001] , which can increase mitochondrial metabolism [Davidson et al. 1989; Halestrap 1989] , attenuate calcium overload [Murata et al. 2001 ] and decrease apoptosis associated with reactive oxygen species generation ]. Therefore, it is plausible that ethanol may activate mitochondrial KATP channels to protect mitochondrial function and thereby diminish oxidative stress to protect the heart from ischemia injury. While Krenz et al. found that the non-specific KATP channel blocker glibenclamide blocked ethanol-mediated preconditioning, the specific mitochondrial KATP channel blocker 5HD did not [Krenz et al. 2002] . They suggest that the effects of 5HD may be unrelated to its effect on mitochondrial KATP channels. Whether ethanol-mediated cardiac protection mimics IPC remains to be determined; however, at least one family of signaling molecules, PKCs, is activated by both protective mechanisms.
The role of PKC isozymes in cardiac ischemia/ reperfusion injury Protein kinase C is a family of serine/threonine phospholipid-dependent kinases [Inoue et al. 1977 ]. The family is encoded by nine genes and is divided into three subclasses based on differences in structure and activation by second messengers. Conventional cPKCs (, , ) are activated by calcium and diacylglycerol whereas novel PKCs (, ", , ) are activated by diacylglycerol but not by calcium. Atypical aPKCs (, /) are insensitive to both second messengers, calcium and diacylglycerol [Mellor and Parker, 1998 ]. Progress in understanding the role of PKC in cardioprotection [Ytrehus et al. 1994 ] was hampered by the lack of isozyme-selective agents [Brooks and Hearse, 1996] . Over the last 15 years, our lab has developed isozyme-selective peptide agonists and antagonists of PKC [Souroujon and Mochly-Rosen, 1998 ]. Based on our observation that the specificity of PKC isozymes is determined by subcellular localization [Mochly- Rosen, 1995] , we proposed that unique localizations are mediated by binding of the activated isozyme to isozyme-specific anchoring proteins, termed RACKs (receptors for activated C-kinase). Therefore, isozyme-specific inhibitors and activators of translocation to the isozyme-specific RACK inhibit or activate the function of the corresponding isozyme.
Using PKC isozyme-selective peptide agonists and antagonists developed based on this hypothesis, we and others have conducted studies in whole heart and in transgenic animals and have demonstrated that an increase in "PKC activation and translocation is sufficient for cardioprotection from ischemia [Takeishi et al. 2000; Dorn et al. 1999; Ping et al. 1999 Ping et al. , 1997 Gray et al. 1997 ]. We also demonstrated that administration of an "PKC agonist peptide into the coronary artery in vivo at the onset of ischemia in pigs decreases infarct size by 60% and completely abolished loss of cardiac function measured 5 days later [Inagaki et al. 2006 . These studies demonstrate that activation of "PKC is sufficient to produce cardioprotection from I/R-induced injury.
In addition to the lack of oxygen and nutrients that can damage the cardiac tissue during an ischemic event, the return of the blood flow (reperfusion) contributes to myocardial injury. Using isozyme-selective inhibitors and activators of PKC, we showed that activation of this isozyme increases cardiac damage due to ischemia and its inhibition at reperfusion in an in vivo porcine model reduces cardiac infarct size by 70% and abolishes cardiac dysfunction when measured after 5 days [Inagaki et al. 2003 ]. The mechanism responsible for this protection was shown to be dependent upon the translocation of PKC to the mitochondria, which was associated with an increase in cytochrome c release into the cytosol and activation of downstream intrinsic apoptotic pathways [Murriel et al. 2004 [Murriel et al. , 2003 . Necrotic pathways are also triggered by PKC translocation to the mitochondria [Churchill et al. 2005; Inagaki et al. 2003 ]. Therefore, it is not surprising that nonselective inhibitors and activators of PKC yielded confusing results [Brooks and Hearse, 1996] ; PKC and "PKC are both activated by ischemia and reperfusion, but they exert opposing roles in cardioprotection; "PKC activation prior to ischemia elicits cardioprotection whereas PKC inhibition protects against reperfusion-induced cell damage. Recently, the peptide inhibitor for PKC, V1-1 (aka KAI-9803) was used in a phase IIa clinical trial in patients with acute myocardial infarction (study conducted by KAI Pharmaceuticals). The trial was not powered to show statistical significance (it included four different cohorts and multiple endpoints of analysis). Nevertheless, the results of the study are encouraging; there were no signs of adverse effects (6% death in placebo and 3% death in drug-treated), and across all dosing cohorts, values of CK-MB (creatine kinase muscle type) AUC (area under the curve), CK-MB estimated peak, and ST segment recovery AUC were all reduced in the group treated with the PKC inhibitor at reperfusion (DELTA-MI Investigators). The mechanisms of PKC and "PKC effects on the ischemic heart have been extensively reviewed in the following reviews and will not be discussed further here [Churchill et al. 2008; Budas et al. 2007a Budas et al. , 2007b Churchill and Mochly-Rosen 2007; Inagaki et al. 2006; Murriel and Mochly-Rosen, 2003 ].
Effect of ethanol on PKC isozymes
Ethanol can both inhibit and increase PKC activity depending on the experimental conditions. Many studies focused on the role of individual PKC isozymes in acute and chronic responses to ethanol by examining the translocation and localization patterns of PKC. Since translocation is a characteristic of PKC activation [Kraft and Anderson, 1983] , further analysis demonstrating changes in kinase activity were rarely included.
It is now known that ethanol can both inhibit and increase PKC activity depending on the experimental conditions. Ethanol-mediated effects on classical PKCs (cPKC) have been studied in the brain.
Although PKC was shown to bind ethanol directly through C1 domain interactions [Newton and Ron, 2007; Stubbs and Slater, 1999] little is known about how it contributes to ethanol-mediated responses. Chronic ethanol consumption causes translocation of PKC and PKC in the hippocampus, but reduces activation of these isozymes in the frontal cortex [Narita et al. 2001 ]. Smith and Bitrick [1996] demonstrated that in vitro chronic exposure of astrocytes to ethanol causes an increase in cPKC activity accompanied by an increase in in situ phosphorylation of MARCKS. Hopf et al. [2005] showed that PKC is a mediator of dopamine-enhanced firing in nucleus accumbens neurons and may play a role in ethanol addiction, but little else is known about the response of atypical PKC isozymes and ethanol.
The regulation of the novel PKC isozymes, PKC and "PKC, has also been studied in the brain. Chronic ethanol administration increases the activation and translocation as well as expression of PKC and "PKC in several brain cell types [Newton and Ron, 2007; Messing et al. 1991 ]. Furthermore, PKC and "PKC both were found to be involved in ethanol-induced increases in the density of L-type voltage-gated calcium channels [McMahon et al. 2000; Gerstin et al. 1998 ]. Finally, Qi et al. [2007] found that "PKC mediates the effects of ethanol by activating GABA(A) receptors through phosphorylation of the gamma-2 subunit. What emerges from studies of the acute effects of ethanol on ion channel function is that inhibition of PKC attenuates the effects of ethanol. Stubbs and Slater [1999] have described many of these effects in a thorough review and they will not be discussed further.
In the heart, we found that a 3-12-week exposure of guinea pigs to 25-50 mM ethanol in their drinking water (17 mM (or 10 mg/ml) blood ethanol levels) prior to ex vivo-induced global ischemia results in a 50% reduction in cardiac damage and a corresponding improvement of cardiac output ]. These effects were associated with sustained activation of "PKC ]. Pretreatment with volatile anesthetics also results in cardioprotection in animals [Novalija et al. 2003; Cope et al. 1997 ] and in humans [Julier et al. 2003] subjected to prolonged ischemia, and similarly, this cardioprotection was associated with activation of "PKC (see Table 2 ). However, it is of interest to note that except for and "PKC, little is known about the effects of ethanol on other PKC isozyme activity in the heart, and it will be interesting to determine if the effect of ethanol on PKC activity in non-cardiac tissue is similar in the heart.
Acute cardioprotective effect of ethanol: dose, timing and washout The finding that ethanol has a direct cardioprotective effect on the I/R challenged myocardium has been reported in a number of studies and in a variety of species including dog, rat, mouse and rabbit Mochly-Rosen, 2001, 1999; Gross et al. 2001; Krenz et al. 2001 ]. Yet some studies have reported a lack of cardioprotective effect of acute administration of ethanol [Hale and Kloner, 2001; Itoya et al. 1998; Bellows et al. 1996] , whereas others have shown that ethanol even prevents endogenous cardioprotection such as that induced by ischemic preconditioning [Niccoli et al. 2008; Krenz et al. 2001] . Therefore, it is evident that the effect of ethanol on the myocardium depends critically on the dose and duration of exposure, the concentration of ethanol present during the ischemic period and the species studied.
We previously reported the acute cardioprotective effect of ethanol (10-50 mM for 10 min prior to ischemia onset) in a simulated ischemia model (using isolated adult rat cardiomyocytes) and in an ex vivo rat heart model consisting of 45 min ischemia followed by 30 min reperfusion (using creatine kinase enzyme release as a marker of cellular necrosis) . It was also found in that study that acute ethanolinduced cardioprotection requires the activation of "PKC , which is central to the signaling of ischemic preconditioning reviewed in [Budas et al. 2007 ]. An acute cardioprotective effect of ethanol in vivo was observed by Krenz et al. [2001] , who also reported that Smith and Bitrick (1996) "PKC ethanol can prevent its own protection if it is not washed out or sufficiently metabolized prior to the onset of ischemia. Using an in vivo rabbit model, Krenz et al. found that ethanol (0.35-1.4 g/kg; serum level 12-26 mM) administered immediately prior to ischemia, did not reduce infarct size induced by 45 min of ischemia followed by 3 h reperfusion. However, when 0.35 g/kg ethanol was infused 1 h prior to the onset of ischemia, at which point ethanol serum levels had dropped to 6 mM, infarct size was significantly reduced [Krenz et al. 2001] . It was thus hypothesized that the continued presence of ethanol during the ischemic episode may interfere with its cardioprotective effect. To test this hypothesis, the authors used an isolated rabbit heart model (in which ethanol can be rapidly washed out) and found that 10-50 mM ethanol administered for 5 min resulted in cardioprotection only when ethanol was washed out for 10 min prior to ischemia onset. Ethanol was also found to be cardioprotective in a hybrid experiment, in which rabbits were administered 0.7 g/kg ethanol intravenously before the heart was rapidly excised and perfused with ethanolfree buffer prior to ischemia onset [Krenz et al. 2001] .
Interestingly, the continued presence of ethanol has also been demonstrated to block the endogenous cardioprotective phenomenon of ischemic preconditioning (IPC) [Niccoli et al. 2008; Krenz et al. 2001] . Krenz et al. [2001] reported that continued presence of ethanol during ischemia blocks IPC-induced cardioprotection in rabbits. These observations have led to the hypothesis that acute ethanol treatment is cardioprotective, but only if ethanol is washed out or at least sufficiently metabolized below a certain threshold prior to the onset of ischemia. More recently, Niccoli et al. [2008] found in humans that the administration of an oral dose of 40 g ethanol (administered as 149 ml of gin) abolished the cardioprotective effect of preconditioning (conferred by repeated balloon inflations) in patients undergoing coronary angioplasty. The finding that the continued presence of ethanol blocks its own protection and that of IPC may actually provide important mechanistic information as to the mechanism of protection. It is possible that ischemia and ethanol share a common detoxification pathway and that continued ethanol presence prevents the removal of toxic ischemic by-products. Removal of acetaldehyde, which is a toxic by-product of ethanol metabolism, may interfere with the detoxification of cytotoxic aldehydes such as 4-HNE and malondialdehyde, which are generated by peroxidation of membrane lipids during cellular stresses such as ischemia and reperfusion and can inactivate both metabolic enzymes and structural proteins by forming protein adducts [McKracken et al. 2001] . Therefore, if ethanol is not sufficiently washed out or metabolized, it may result in accumulation of reactive aldehydes, which could lead to protein-adduct formation and worsening of cellular injury.
Another explanation for these different effects of ethanol is that ethanol activates two protein kinase C isozymes that exert opposing roles in cell survival ; "PKC, which mediates cardioprotection Mochly-Rosen, 2001, 1999; Dorn et al. 1999] and PKC, which mediates injury induced by cardiac reperfusion [Inagaki et al. 2003 ]. Chen et al. demonstrated that ethanol treatment induces the translocation of both "PKC and PKC, but that only "PKC inhibition prevents ethanol-induced protection. We subsequently found that "PKC and PKC mediate distinct temporal roles in the response of the myocardium to acute ethanol treatment, an effect that was also critically dependent on ethanol dose . In that study, mice were administered with ethanol (0.1 g/kg and 0.5 g/kg) intra-peritoneally 10, 60 or 90 min prior to 30 min of ischemia followed by 120 min of reperfusion (performed on isolated perfused hearts). Injection of 0.1 g/kg immediately prior to ischemia confers cardioprotection that lasts up to 60 min, whereas injection of 0.5 g/kg ethanol produces protection only after a 60 min delay. Translocation analysis revealed that 0.1 g/kg ethanol resulted in translocation of "PKC, but not PKC, after 10 and 60 min. Injection of 0.5 g/kg ethanol, however, resulted in translocation of both PKC and "PKC, suggesting that at a higher dose of ethanol (0.5 g/kg), PKC activation may attenuate the ethanol-induced cardioprotection mediated by "PKC. Unexpectedly however, when the PKC inhibitor, V1-1, was injected 10 min before ethanol injection, the cardioprotective effect induced by 0.5 g/kg ethanol after 60 min was partly abolished, suggesting that PKC may contribute to the cardioprotection observed after 60 min. To determine how PKC can contribute to cardioprotection after 60 min, mice were injected with the PKC activator, RACK, and isolated hearts exposed to IR. It was found that RACK injection 60 and 90 minutes (but not 10 min) before IR resulted in cardioprotection, which could be blocked by the selective "PKC inhibitor "V1-2. RACKinduced protection was also blocked by the A1 adenosine receptor antagonist, DPCPX. This led to the hypothesis that ethanol-induced PKC activation at high doses (such as 0.5 g/kg) stimulates adenosine secretion, leading to A1 adenosine receptor activation, resulting in the activation of "PKC, which leads to cardioprotection after 1 h ethanol administration (Figure 1 ). A1 adenosine receptor occupancy could have occurred due to an increase in intracellular adenosine synthesis or an increase in adenosine transport by the equilibrative nucleoside transporter 1 (ENT1) which has been demonstrated to be regulated by PKC [Chaudary et al. 2004a [Chaudary et al. , 2004b Coe et al. 2002] . At lower doses (i.e. 0.1 g/kg), ethanol stimulates the cardioprotective "PKC isozyme, but not the damaging PKC enzyme, thus conferring acute protection after only 10 min (Figure 1) . It is therefore evident that the dose and timing of ethanol administration is critical to induce a cardioprotective effect without blocking endogenous cardioprotective signaling and that this narrow therapeutic window must be taken into consideration in any future clinical studies.
Therapeutic implications
Ethanol is a cheap, readily available drug that is consumed by 70% of the adult population in the US [Who, 2004] . The evidence supporting the beneficial effects of ethanol on the heart is abundant. Although the proper timing and dosage need to be carefully considered, ethanol may be an effective and inexpensive treatment for patients with predicted ischemia such as those undergoing coronary artery bypass surgery (CABG) or organ transplantation. However, further studies should examine the timing and dose of ethanol treatment that will provide the optimal protection to patients.
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